dc.contributor.author | Albayrak, Yakup | |
dc.contributor.author | Hashimoto, Kenji | |
dc.date.accessioned | 2022-05-11T14:41:06Z | |
dc.date.available | 2022-05-11T14:41:06Z | |
dc.date.issued | 2017 | |
dc.identifier.isbn | 978-3-319-50174-1 | |
dc.identifier.isbn | 978-3-319-50172-7 | |
dc.identifier.issn | 0065-2598 | |
dc.identifier.issn | 2214-8019 | |
dc.identifier.uri | https://doi.org/10.1007/978-3-319-50174-1_11 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/9063 | |
dc.description.abstract | Accumulating evidence suggests that sigma-1 receptors play a role in the pathophysiology of neuropsychiatric diseases, as well as in the mechanisms of some selective serotonin reuptake inhibitors (SSRIs). Among the SSRIs, the order of affinity for sigma-1 receptors is as follows: fluvoxamine > sertraline > fluoxetine > escitalopram > citalopram >> paroxetine. Some SSRIs (e.g., fluvoxamine, fluoxetine and escitalopram) and other drugs (donepezil, ifenprodil, dehydroepiandeterone (DHEA)) potentiate nerve-growth factor (NGF)-induced neurite outgrowth in PC12 cells, and these effects could be antagonized by the selective sigma-1 receptor antagonist NE-100. Furthermore, fluvoxamine, donepezil, and DHEA, but not paroxetine or sertraline, improved phencyclidine-induced cognitive deficits in mice, and these effects could be antagonized by NE-100. Several clinical studies showed that sigma-1 receptor agonists such as fluvoxamine and ifenprodil could have beneficial effects in patients with neuropsychiatric disorders. In this chapter, the authors will discuss the role of sigma-1 receptors in the mechanistic action of some SSRIs, donepezil, neurosteroids, and ifenprodil, and the clinical implications for sigma-1 receptor agonists. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer International Publishing Ag | en_US |
dc.identifier.doi | 10.1007/978-3-319-50174-1_11 | |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Donepezil | en_US |
dc.subject | Ifenprodil | en_US |
dc.subject | Fluvoxamine | en_US |
dc.subject | Psychiatric diseases | en_US |
dc.subject | Serotonin Reuptake Inhibitors | en_US |
dc.subject | Improved Cognitive Impairments | en_US |
dc.subject | Positron-Emission-Tomography | en_US |
dc.subject | H-3 Ifenprodil Binding | en_US |
dc.subject | Double-Blind | en_US |
dc.subject | Delusional Depression | en_US |
dc.subject | Schizophrenia Report | en_US |
dc.subject | Tardive-Dyskinesia | en_US |
dc.subject | Neurite Outgrowth | en_US |
dc.subject | Therapeutic Drugs | en_US |
dc.title | Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders | en_US |
dc.type | bookPart | en_US |
dc.relation.ispartof | Sigma Receptors: Their Role in Disease and As Therapeutic Targets | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Ruh Sağlığı ve Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-8892-0439 | |
dc.identifier.volume | 964 | en_US |
dc.identifier.startpage | 153 | en_US |
dc.identifier.endpage | 161 | en_US |
dc.institutionauthor | Albayrak, Yakup | |
dc.coverage.doi | 10.1007/978-3-319-50174-1 | |
dc.relation.publicationcategory | Kitap Bölümü - Uluslararası | en_US |
dc.authorscopusid | 29067508300 | |
dc.authorscopusid | 55365316700 | |
dc.authorwosid | Albayrak, Yakup/ABA-7651-2020 | |
dc.authorwosid | Hashimoto, Kenji/I-5800-2015 | |
dc.identifier.wos | WOS:000412315600012 | en_US |
dc.identifier.scopus | 2-s2.0-85015900607 | en_US |
dc.identifier.pmid | 28315270 | en_US |